Drug Profile
Lidocaine intradermal - Anesiva/Powder Pharmaceuticals/Lee's Pharmaceuticals
Alternative Names: ALGRX 3268; D-4115; Lidocaine microcrystals; PowderJect Dermal Lignocaine; PowderJect Lidocaine; ZingoLatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Anesiva
- Developer Anesiva; Lee's Pharmaceutical; Marathon Pharmaceuticals
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaesthesia
Most Recent Events
- 10 Mar 2023 Lidocaine is still in registration phase for anaesthesia in China (Lees Pharmaceutical website, March 2022)
- 10 Mar 2023 Registered for Anaesthesia (In children) in China (Intradermal) (Lees Pharmaceutical website, March 2022)
- 17 Feb 2021 Lidocaine intradermal is still in phase III trials for Anaesthesia (In children) in China (Intradermal)